Failed study, dimmed hopes in hunt for Alzheimer's treatment


A treatment for Alzheimer's failed to slow mental decline in a widely anticipated study, ending hope that researchers at Eli Lilly had finally found a drug that does more to help those suffering from the fatal, mind-robbing disease. The drug, solanezumab, missed the study's main goal when patients taking it did not experience a statistically significant slowing of cognitive decline - which involves a person's ability to remember things - compared to those taking a placebo or fake drug.



from Biotech News